Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06668571 · ClinicalTrials.gov registry record · Phase 2
Intravenous Ketamine for Treatment-Resistant Depression
A Phase 2 study of Depressive Disorder, Treatment-Resistant and Treatment Resistant Depression (TRD), sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06668571: Recruiting Phase 2 study of Depressive Disorder, Treatment-Resistant and Treatment Resistant Depression (TRD), sponsored by Mayo Clinic.
NCT06668571 is a Phase 2 study of Depressive Disorder, Treatment-Resistant and Treatment Resistant Depression (TRD) that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 234-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06668571, a Phase 2 study of Depressive Disorder, Treatment-Resistant and Treatment Resistant Depression (TRD), is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.
Primary Outcome
To measure peak (% change from baseline) Anterior Cingulate Cortex (ACC) Gamma-Aminobutyric Acid (GABA) and Glutamate (Glu) levels during a 40-minute IV ketamine or normal saline (0.9% sodium chloride) infusion utilizing fMRS (functional Magnetic Resonance Spectroscopy)
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Normal Saline
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06668571 shows while recruiting
NCT06668571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 234-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Depressive Disorder, Treatment-Resistant appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT06668571 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06668571 about?
NCT06668571 is a clinical study titled "Intravenous Ketamine for Treatment-Resistant Depression". The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with ...
What is the current status of trial NCT06668571?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-02-10. Estimated completion is 2027-12-31.
What conditions does trial NCT06668571 study?
This clinical trial studies the following conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD).
What interventions are being tested in trial NCT06668571?
The interventions under investigation include: Ketamine (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT06668571?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06668571 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Treatment-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06668571's enrollment target sits among peer trials
30 9th of 9 higher than 1 of 9 other Depressive Disorder, Treatment-Resistant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Treatment-Resistant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
Dopaminergic Dysfunction in Late-Life Depression
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
COMPLETED · Phase 2
-
Improving Brain Stimulation Through Imaging
ACTIVE NOT RECRUITING
-
Adaptive tDCS for Treatment-Resistant MDD
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI